
## **Rajesh Chavan**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/292527/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In-vitro antibacterial activity of Fosfomycin and Nitrofurantoin against Pseudomonas aeruginosa and Acinetobacter baumannii against clinical isolates collected from Indian tertiary care hospitals. Journal of Drug Delivery and Therapeutics, 2022, 12, 26-32.	0.5	0
2	Assessment of the <i>in vitro</i> cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. Xenobiotica, 2021, 51, 251-261.	1.1	5
3	Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog. Regulatory Toxicology and Pharmacology, 2021, 122, 104889.	2.7	2
4	Assessment of <i>inÂvitro</i> inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica, 2020, 50, 1149-1157.	1.1	4
5	<i>In Vivo</i> Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
6	Safety, Tolerability, and Pharmacokinetics of Oral Nafithromycin (WCK 4873) after Single or Multiple Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
7	<p>Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence</p> . Drug Design, Development and Therapy, 2019, Volume 13, 4351-4365.	4.3	44
8	WCK 4873 (Nafithromycin): Assessment of In Vitro Human CYP Inhibitory Potential of a Novel Lactone-Ketolide. Open Forum Infectious Diseases, 2016, 3, .	0.9	8